Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5328539 | 0.91 | HTR1A (0.52) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL5333200 | 0.91 | HTR1A (0.46) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL5329995 | 0.90 | HTR1A (0.41) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL4525015 | 0.90 | HTR1A (0.55) | HTR1AHTR7DRD2HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL4527605 | 0.89 | HTR1A (0.54) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL5327372 | 0.88 | HTR1A (0.48) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL5328358 | 0.88 | RAB9A (0.43) | HTR1AHTR7DRD2HTR2AHTR6 | |
| Phosphoric Acid SCHEMBL5325027 | 0.87 | HTR1A (0.47) | HTR1AHTR7DRD2HTR2AHTR6 | |
| Phosphoric Acid SCHEMBL5327365 | 0.86 | HTR1A (0.49) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL4527313 | 0.85 | HTR1A (0.49) | HTR1AHTR7DRD2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007010504-A2 | ACID ADDITION SALTS OF ISOINDOLES ACTING AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-25 | — | — | WO | disclosed |